Nonspecific immunity to SARS-CoV-2 by MTBVAC plus BCG tuberculosis vaccine | Pandemic PACT Tracker

Key facts

Disease
COVID-19
Known Financial Commitments (USD)
$343,440
Funder
National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)
Principal Investigator
Pending
Research Location
Spain
Lead Research Institution
Universidad de Zaragoza.
Research Priority Alignment
N/A

Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Immunity
Special Interest Tags
N/A
Study Subject
Unspecified
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable

Abstract

Nonspecific immunity to SARS-CoV-2 by MTBVAC plus BCG tuberculosis vaccine